list 페이지

Stock issuance

Dec 05, 2018PRESS RELEASES

MedPacto Announces Clinical Collaboration with MSD to Evaluate Vactosertib, an Investigational TGF-β Type I Receptor Inhibitor, in combination with KEYTRUDA® (pembrolizumab)

Jul 24, 2018PRESS RELEASES

MedPacto Announces Immuno-Oncology Clinical Trial Collaboration with AstraZeneca

Jul 24, 2018PRESS RELEASES

Announcement of the closing date of shareholder list

Jun 04, 2018PRESS RELEASES

Stock issuance

Mar 27, 2018PRESS RELEASES

Stock issuance

Feb 08, 2018PRESS RELEASES

Stock issuance

Dec 18, 2017PRESS RELEASES

The office of MedPacto, Inc. was relocated to new place with its research center.

Sep 15, 2016EVENTS

Temporary meeting of the board of directors

Sep 06, 2016PRESS RELEASES

The MedPacto Inc. board has appointed Dr. Seong-Jin Kim as a co-chief executive officer

Aug 25, 2016PRESS RELEASES

Announcement: 3rd annual general meeting of stockholders

Mar 07, 2016PRESS RELEASES

Collaboration with ANRT

Sep 10, 2015PRESS RELEASES

Phase I clinical trial dose escalation - 4th cohort

Sep 09, 2015MILESTONES

Announcement: 2nd annual general meeting of stockholders

Feb 11, 2015PRESS RELEASES

Completion of the second cohort of TEW-7197 and SMC decided to escalate to the next dose.

Jan 20, 2015MILESTONES

Safety Monitoring Committee (SMC) reviewed safety of the first cohort of TEW-7197 and decided to escalate to the next dose.

Oct 21, 2014MILESTONES

Temporary meeting of the board of directors

Aug 13, 2014PRESS RELEASES

The first dosing of TEW-7197 in a cancer patient in the USA

Aug 05, 2014MILESTONES

Clinical trial of TEW-7197 starts its first step.

Jul 17, 2014MILESTONES

MedPacto gets an approval of IND for TEW-7197 from US FDA

May 19, 2014MILESTONES

MedPacto, Inc. and OncoVenture have submitted IND application to US FDA for Medpacto's oral ALK5 inhibitor, TEW-7197.

Apr 03, 2014MILESTONES

Announcement: An annual general meeting of stockholders

Feb 06, 2014PRESS RELEASES

National OncoVenture (NOV) announces the support of development of MedPacto’s leading anticancer drug candidate, TEW-7197

Nov 05, 2013PRESS RELEASES